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Gastrointestinal Endoscopes
A Need to Shift From Disinfection to Sterilization?
William A. Rutala, PhD, MPH; David J. Weber, MD, MPH
More than 10 million gastrointestinal endoscopic procedures
are performed annually in the United States for diagnostic pur-
poses, therapeutic interventions, or both.1 Because gastroin-
testinal endoscopes contact mucosal surfaces, use of a contami-
nated endoscope may lead to patient-to-patient transmission
of potential pathogens with a subsequent risk of infection.1
In this issue of JAMA, Epstein and colleagues2 report find-
ings from their investigation of a cluster of New Delhi metallo-
β-lactamase (NDM)–producing Escherichia coli associated with
gastrointestinal endoscopy that occurred from March 2013 to
July 2013 in a single hospital in
northeastern Illinois. During
the 5-month period, 9 pa-
tients with positive cultures
for NDM-producing E coli were identified, and a case-control
study demonstrated that a history of undergoing an endo-
scopic procedure at this specific hospital was strongly associ-
ated with cases of NDM-producing E coli. Cultures obtained from
the endoscope used on 5 of the case patients yielded an NDM-
producing E coli from the elevator channel. The elevator chan-
nel is unique to side-viewing endoscopes, most often used to
perform endoscopic retrograde cholangiopancreatography
(ERCP). The elevator has a separate channel and provides ori-
entation of catheters, guide wires, and accessories into the en-
doscopic visual field. This channel is complex in design and may
be more difficult to disinfect completely.
The E coli isolate was highly related (>92%) to all case patient
isolatesbypulsed-fieldgelelectrophoresis.Endoscopereprocess-
ing procedures were reviewed and no lapses were identified. Fur-
ther, the automated endoscope reprocessor (AER) was function-
ing correctly and the duodenoscopes were not damaged. The
facility notified the 226 patients who had potential exposure to
a culture-positive endoscope. Twenty-seven additional case pa-
tients were identified by active surveillance who were colonized
and had been exposed to a duodenoscope. No additional cases
were identified after the hospital changed its endoscope repro-
cessing from automated high-level disinfection with ortho-
phthalaldehyde to gas sterilization with ethylene oxide.
The key concern raised by this study is whether current
US endoscope reprocessing guidelines are adequate to en-
sure a patient-safe gastrointestinal endoscope (one devoid of
potential pathogens) or if endoscopes with their long, narrow
channels, right-angle turns, difficult to clean and disinfect com-
ponents, and heavy microbial contamination impossible to re-
liably high-level disinfect. To examine this concern and offer
recommendations, understanding current knowledge on en-
doscope reprocessing is necessary.
First, endoscopes are semicritical devices, which contact
mucous membranes or nonintact skin, and require at least high-
level disinfection.3,4 High-level disinfection achieves complete
elimination of all microorganisms, except for small numbers of
bacterial spores. Because flexible gastrointestinal endoscopic
instruments are heat labile, only high-level disinfection with
chemical agents or low-temperature sterilization technologies
are possible.3 However, no low-temperature sterilization tech-
nology is US Food and Drug Administration (FDA)–cleared for
gastrointestinal endoscopes such as duodenoscopes.
Second, more health care–associated outbreaks and clus-
ters of infection have been linked to contaminated endo-
scopes than to any other medical device.3,5 However, until now,
these episodes have been traced to deficient practices such as
inadequate cleaning, inappropriate disinfection, and dam-
aged endoscopes or flaws in the design of endoscopes or AERs.3
In addition, reprocessing failures have led to patient notifica-
tions and blood-borne pathogen testing in dozens of instances.6
Third, evidence-based endoscope reprocessing guidelines
have been prepared by professional organizations and the Cen-
ters for Disease Control and Prevention (CDC). Although some
data have demonstrated that rigorous adherence to these guide-
lines will result in a patient-safe endoscope,3,4 other data have
demonstrated that all of the steps associated with manual endo-
scope reprocessing are rarely performed and some essential steps
(eg, brushing all endoscope channels and components) are com-
monly skipped.7 Endoscope reprocessing was improved with the
use of AERs because most steps were automated.7
Fourth, endemic transmission of infections associated with
gastrointestinal endoscopes may be unrecognized due to in-
adequate surveillance of outpatient procedures, long lag time
between colonization and infection, and a low frequency of
clinical infection. Additionally, the risk for some procedures
might be higher than others in which normally sterile areas are
contaminated. In the cluster of cases identified by Epstein et
al, the presence of an unusual pathogen (NDM-producing E coli)
prompted an investigation and subsequent recognition that
duodenoscopes were the source of the case patient isolates.2
Fifth, the margin of safety associated with reprocessing en-
doscopes is minimal. Endoscopes are heavily contaminated with
microbes. The internal channel of gastrointestinal endoscopes
may contain 108-10 (8-10 log10) enteric microorganisms.8 The
cleaning step in endoscope reprocessing results in a 4 to 6 log10
reduction of microbes and the high-level disinfection step re-
sults in another 4 to 6 log10 reduction of mycobacteria, for a total
8 to 12 log10 reduction of microbes.9 Thus, the margin of safety
associated with cleaning and high-level disinfection of gastro-
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intestinal endoscopes is minimal (0-2 log10 margin of safety).
Therefore, any deviation from proper reprocessing could result
in the failure to eliminate contamination with a possibility of sub-
sequent patient-to-patient transmission. This low margin of
safety associated with endoscope reprocessing compares with
the 17 log10 margin of safety associated with cleaning and ster-
ilization of surgical instruments.10,11
What should be done to ensure the safety of these commonly
used devices? The enforcement of best practices including equip-
ment maintenance and routine audits with at least yearly com-
petency testing of staff who use the reprocessing equipment is
imperative. But if adherence to regulation is lax, more outbreaks
will likely occur. Obtaining additional information on the fre-
quency and level of microbial contamination of endoscopes that
have been cleaned and high-level disinfected with strict adher-
ence to current guidelines will be helpful in defining the extent
of the problem. If endoscopes are found to be contaminated with
potential pathogens (eg, enteric gram-negative bacilli), the clini-
cal effects of such contamination need to be quantified.
In addition, better approaches to assess the effectiveness
of cleaning and high-level disinfection are needed. Although
microbiological cultures are the gold standard, they cannot be
used as a real-time monitoring process. However, based on the
study by Epstein et al, it would be reasonable to perform peri-
odic microbiological surveillance of duodenoscopes to assess
microbial contamination, although many questions remain.
These include the following: (1) What cutoff should be used to
define proper disinfection (eg, 0 pathogens or a higher num-
ber, such as <10 colony-forming units of enteric pathogens per
channel)? (2) What sampling scheme should be used to evalu-
ate gastrointestinal endoscopes (eg, all or a sample of endo-
scopes)? (3) Is the trigger for further action based on the level
or the frequency of contamination (ie, percent of endoscopes
contaminated)? (4) What actions should an endoscopy unit
undertake if a positive trigger is reached based upon the level
or frequency of contamination (ie, patient notification with an
offer of blood-borne pathogen testing, ethylene oxide steril-
ization of positive endoscopes, or ethylene oxide sterilization
of all endoscopes)? Real-time monitoring methods need to be
developed and validated to assess the risk of infection.
Moreover, adequate resources must be provided by the
manufacturers of endoscopes, AERs, high-level disinfectants,
andsterilizationtechnologiesaswellasfederalauthorities(CDC,
FDA, and National Institutes of Health) to design and complete
the necessary studies to determine the risks posed by current
reprocessing of endoscopes and develop new reprocessing
methods and practices. In addition, new endoscope reprocess-
ing technologies need to be developed that reliably result in
sterilization of gastrointestinal endoscopes via an FDA-cleared
sterilization process, which would greatly improve the margin
of safety. Alternatively, development of sterile disposable
gastrointestinal endoscopes or a shift to other sterile diagnos-
tic modalities should be considered. Ethylene oxide steriliza-
tion, which was used to terminate this cluster of endoscope-
related infections,2 is not a long-term satisfactory solution as it
has not been FDA-cleared for sterilizing gastrointestinal endo-
scopes, many hospitals no longer have ethylene oxide, and the
sterilization and aeration time is long (12-15 hours).
Finally, clinicians should be encouraged to report and pub-
lish cases of infectious diseases related to endoscopy, especially
if current reprocessing methods were adhered to, so it can be de-
termined if the report by Epstein et al2 is the tip of the iceberg or
an isolated occurrence. If the former, then revision of the endo-
scope reprocessing guidelines will be necessary to ensure patient
safety. However, regardless of when these issues are resolved,
endoscopy will remain an important diagnostic and therapeutic
modality and should continue to be used while clinicians strictly
adhere to current endoscope reprocessing guidelines.3,4
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